Clinical Trials Logo

Acute Myocarditis clinical trials

View clinical trials related to Acute Myocarditis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04375748 Completed - Acute Myocarditis Clinical Trials

Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases

MYOCOVID
Start date: April 15, 2020
Phase:
Study type: Observational

To date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood. The current pandemic of this emerging virus is an opportunity to assess the proportion of acute myocarditis attributable to SARS-Cov-2(Covid-19) and to assess the clinical, biological and imaging presentations, by means of a national prospective multicentre hospital registry of cases of acute myocarditis.

NCT ID: NCT03018834 Completed - Acute Myocarditis Clinical Trials

Anakinra Versus Placebo for the Treatment of Acute MyocarditIS

ARAMIS
Start date: May 30, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

There is no specific treatment of acute myocarditis, especially during the inflammatory period. Interleukin (IL) is specifically involved during this period and play a role in myocardial oedema. ANAKINRA, an IL-1β Blocker, is a new treatment that has never been evaluated in myocarditis. The benefit for the patient could be important with a reduction of heart failure and ventricular arrhythmias. Hypothesis : ANAKINRA in addition to standard therapy for treatment of Acute Myocarditis is superior to standard therapy based on an association of beta-blockers and Angiotensin-Converting-Enzyme inhibitor (ACE).